secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cue Biopharma, Inc. (CUE)
CIK:        0001645460
Form:       8-K
Filed at:   2026-02-12T23:59:59+00:00
Accession:  0001193125-26-047717
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Cue Biopharma appoints CBO Lucinda Warren as CFO effective Feb 9, 2026
----------------------------------------------------------------------

- Lucinda Warren, previously CBO, named Chief Financial & Business Officer; assumes principal financial/accounting officer duties.
- Warren had been CBO since Sept 2024; prior VP Business Development at Johnson & Johnson (2014-2024).
- No additional compensation or changes to her employment agreement for the CFO role.
- No family relationships with directors/officers; no reportable transactions under Item 404(a).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645460/000119312526047717/0001193125-26-047717-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645460/000119312526047717/cue-20260209.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-047717

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer